Please assess the completion status of the following clinical trial:

Trial Title: Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 4 years old~* parasite count ≥ 1,000 asexual parasites/µL~* normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (Trinity Biotech® no 203, USA)~* hemoglobin level ≥ 8 gr/dL as measured by Hemoque® apparatus;~* have the ability to return for 42-day-follow up and~* willingness to sign the informed-consent form.~Exclusion Criteria:~* are infected with other r plasmodium species~* have only gametocytes of P. falciparum;~* are pregnant - measured by positive result on HCG urine test and/or breastfeeding women~* present signs of pitting edema on both legs as a sign of malnutrition~* have complicated or severe malaria, other chronic diseases or history of drug allergies.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): None
- Dihydroartemisininpiperaquine primaquine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).